Evidence map›Paper›PMID 40124372›Full record

Observational studyFrontiers in immunology2025

Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study.

Dong Zhao, Minghong Bi, Xiaofei Cheng, Shuhong Wang, Huaidong Cheng, Xiaoyang Xia, Huan Chen, Yanbei Zhang, Zhiqiang Hu, Qisheng Cao and 11 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Dong ZhaoDepartment of Oncology, Lixin County People's Hospital, Bozhou, China.
Minghong BiDepartment of Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Xiaofei ChengDepartment of Oncology, Anqing Hospital of Navy, Anqing, China.
Shuhong WangDepartment of Oncology, Huangshan City People's Hospital, Huangshan, China.
Huaidong ChengDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Xiaoyang XiaDepartment of Oncology, Chuzhou City First People's Hospital, Chuzhou, China.
Huan ChenDepartment of Pulmonary and Critical Care Medicine, Anqing Hospital of Navy, Anqing, China.
Yanbei ZhangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhiqiang HuDepartment of Oncology, Huaibei Miner General Hospital, Huaibei, China.
Qisheng CaoInterventional Oncology, Maanshan City People's Hospital, Maanshan, China.
Hui LiangDepartment of Radiology, Traditional Chinese Hospital of LuAn, Luan, China.
Fan WangDepartment of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xuhong MinDepartment of Radiology, Anhui Chest Hospital, Hefei, China.
Ling XuDepartment of Pulmonary and Critical Care Medicine, Anhui Chest Hospital, Hefei, China.
Kehai FengDepartment of Oncology, The First Affiliated Hospital of USTC West District, Hefei, China.
Jinhua ZhouDepartment of Oncology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China.
Xinzhong LiDepartment of Oncology, Huaibei City People's Hospital, Huaibei, China.
Rui WangDepartment of Oncology, Anhui Chest Hospital, Hefei, China.
Hua XieDepartment of Oncology, Xuancheng City People's Hospital, Xuancheng, China.
Xiaosi ChenDepartment of Oncology, Dangtu County People's Hospital, Maanshan, China.
Kangsheng GuDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Camrelizumab, a programmed death-1 inhibitor, is effective and safe for treating patients with advanced lung cancer according to previous phase 3 trials. However, relevant real-world clinical evidence is required. This study intended to explore the efficacy and safety of camrelizumab-based therapies in patients with advanced lung cancer. Methods: Patients with advanced lung cancer who received camrelizumab-based therapies as first-line or above treatment were consecutively enrolled in this study. The median follow-up duration was 5 months. Results: A total of 298 subjects were enrolled. Objective response rate (ORR) and disease control rate (DCR) were 27.2% and 82.2%. Multivariable logistic regression analysis showed that previous pulmonary surgery [odds ratio (OR)=0.440, Conclusions: Camrelizumab-based therapies may serve as potential treatments for patients with advanced lung cancer. However, further studies with an extended follow-up duration are warranted.

Indexed as

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsLung NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingProspective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedcamrelizumabImmune Checkpoint Inhibitorsadvanced lung canceradverse eventscamrelizumab-based therapiessurvivaltreatment response

Identifiers

PMID40124372
PMCPMC11925761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.